NDA 020186 · Teva Branded Pharm
Ziac
Bisoprolol Fumarate, Hydrochlorothiazide · Oral · Thiazide Diuretic
Last checked: Nov 19, 2026Latest source record: Jul 24, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1993
Mar 26, 1993
Approved uses
1
Original approval plus efficacy supplements
Registered trials
122
17 Phase 3, 16 recruiting
FAERS reports
620
443 serious, 54 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Aug 11, 2026.
INDICATIONS AND USAGE Bisoprolol fumarate and hydrochlorothiazide tablets are indicated in the management of hypertension.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Mar 26, 1993 Original approval · Type 4 - New Combination
3 products under this application
- ZIAC · BISOPROLOL FUMARATE 2.5MG; HYDROCHLOROTHIAZIDE 6.25MG · TABLET, ORAL · Prescription · TE AB
- ZIAC · BISOPROLOL FUMARATE 5MG; HYDROCHLOROTHIAZIDE 6.25MG · TABLET, ORAL · Prescription · TE AB
- ZIAC · BISOPROLOL FUMARATE 10MG; HYDROCHLOROTHIAZIDE 6.25MG · TABLET, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Bisoprolol" as an intervention, any sponsor and status, largest first.
- TREatment With Beta-blockers After myOcardial Infarction withOut Reduced Ejection fracTion"Pivotal-lookingCompleted
Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos IIIAcademic, hospital or other
NCT03596385 · 8,505 participants · Start Oct 31, 2018 · Primary completion Jan 31, 2025
Drug: Beta blocker · For: Myocardial Infarction
Sites: San Severo, Italy; Alessandria, Italy; Ancona, Italy · 111 sites in all
- Evaluation of Decreased Usage of Betablockers After Myocardial Infarction in the SWEDEHEART Registry (REDUCE-SWEDEHEART)Pivotal-lookingStatus unknown
Karolinska InstitutetAcademic, hospital or other
NCT03278509 · 5,000 participants (planned) · Start Sep 11, 2017 · Primary completion Nov 16, 2023
Drug: Metoprolol Succinate; Bisoprolol · For: Acute Myocardial Infarction; Non-ST Elevation Myocardial Infarction; ST Elevation Myocardial Infarction
Sites: Danderyd, Sweden
- BEtablocker Treatment After Acute Myocardial Infarction in Patients Without Reduced Left Ventricular Systolic FunctionPivotal-lookingActive, not recruiting
Oslo University HospitalAcademic, hospital or other
NCT03646357 · 2,895 participants · Start Oct 1, 2018 · Primary completion Apr 4, 2025
Drug: Betablocker · For: Acute Myocardial Infarction; Non-ST Elevation Myocardial Infarction; ST Elevation Myocardial Infarction
Sites: Arendal, Norway; Bergen, Norway; Bodø, Norway · 20 sites in all
- Danish Trial of Beta Blocker Treatment After Myocardial Infarction Without Reduced Ejection FractionPivotal-lookingActive, not recruiting
Bispebjerg HospitalAcademic, hospital or other
NCT03778554 · 2,760 participants (planned) · Start Dec 17, 2018 · Primary completion Apr 1, 2025
Drug: Metoprolol Succinate; Bisoprolol and 2 more · For: Acute Myocardial Infarction; Non-ST Elevation Myocardial Infarction (nSTEMI); ST Elevation Myocardial Infarction
Sites: Copenhagen, Denmark
- NT-proBNP Selected Prevention of Cardiac Events in Diabetic PatientsPivotal-lookingRecruiting
Martin HuelsmannAcademic, hospital or other
NCT02817360 · 2,400 participants (planned) · Start Feb 2016 · Primary completion Dec 2025
Drug: RAS-antagonist and beta-blocker up-to maximal dosages · For: Heart Diseases; Diabetes Mellitus, Type 2
Sites: Mödling, Austria; Graz, Austria; Linz, Austria · 21 sites in all
- HFrEF Polypill in Sri Lanka RCTPivotal-lookingRecruiting
Washington University School of MedicineAcademic, hospital or other
NCT07569640 · 1,672 participants (planned) · Start Aug 17, 2026 · Primary completion Apr 2029
Drug: HFrEF Polypill · For: Heart Failure With Reduced Ejection Fraction
Sites: Kandy, Sri Lanka; Anuradhapura, Sri Lanka; Kurunegala, Sri Lanka · 12 sites in all
- Beta-blOckers discoNtinuation in Patients Presenting Heart FaIlure With REcovered Left Ventricular Ejection FractionPivotal-lookingRecruiting
Assistance Publique - Hôpitaux de ParisAcademic, hospital or other
NCT06518694 · 1,300 participants (planned) · Start Feb 11, 2025 · Primary completion Oct 2027
Drug: Βeta-Blockers discontinued (with tapering) · For: Heart Failure
Sites: Paris, France
- Different β -Blockers in STEMI and Primary PCIPivotal-lookingStatus unknown
Qilu Hospital of Shandong UniversityAcademic, hospital or other
NCT04221919 · 1,200 participants (planned) · Start Jan 2020 · Primary completion Jan 2021
Drug: β -Blockers · For: Primary PCI
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- headache50
- fatigue44
- drug ineffective43
- nausea42
- pruritus39
- pain38
- hypertension37
- vomiting36
- diarrhoea33
- rash33
- dyspnoea32
- arthralgia31
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 22 |
| 2005 | 39 |
| 2006 | 18 |
| 2007 | 33 |
| 2008 | 41 |
| 2009 | 42 |
| 2010 | 75 |
| 2011 | 64 |
| 2012 | 95 |
| 2013 | 5 |
| 2014 | 7 |
| 2015 | 12 |
| 2016 | 20 |
| 2017 | 19 |
| 2018 | 24 |
| 2019 | 14 |
| 2020 | 12 |
| 2021 | 15 |
| 2022 | 15 |
| 2023 | 8 |
| 2024 | 14 |
| 2025 | 14 |
| 2026 | 12 |
Recalls
1 FDA enforcement reports for this application.
Mar 15, 2021 · Class II · Terminated
CGMP Deviations: Intermittent exposure to temperature excursion during storage.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Ziac (Bisoprolol/Hydrochlorothiazide)
2024 spending
$38K
Beneficiaries
18
37 claims
Per beneficiary
$2,119
$8.14 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $163,421 |
| 2021 | $130,971 |
| 2022 | $132,871 |
| 2023 | $112,270 |
| 2024 | $38,147 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Beta-Blockers after Myocardial Infarction and Preserved Ejection Fraction.
Yndigegn T, Lindahl B, Mars K, et al. · N Engl J Med 2024 · Multicenter Study, Randomized Controlled Trial
- The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial.
· Lancet 1999 · Clinical Trial, Comparative Study
- Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial.
Williams B, MacDonald TM, Morant S, et al. · Lancet 2015 · Comparative Study, Randomized Controlled Trial
- Beta-blocker therapy in heart failure with preserved ejection fraction (B-HFpEF): A systematic review and meta-analysis.
Kaddoura R, Madurasinghe V, Chapra A, et al. · Curr Probl Cardiol 2024 · Meta-Analysis, Systematic Review
- Beta-blockers for the treatment of arrhythmias: Bisoprolol - a systematic review.
Muresan L, Cismaru G, Muresan C, et al. · Ann Pharm Fr 2022 · Systematic Review
- A Systematic Literature Review and Network Meta-analysis of Azilsartan Medoxomil Compared to Other Anti-hypertensives Efficacy in Lowering Blood Pressure Amongst Mild to Moderate Hypertensive Patients.
Qian J, Zhang M, Chen Z · Adv Ther 2024 · Systematic Review, Comparative Study
Sponsor: Teva
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.